efficacy of 2013 ACC/AHA guideline in primary prevention of coronary artery disease (CAD)
Phase 2
- Conditions
- Coronary artery disease.Chronic ischemic heart disease
- Registration Number
- IRCT20181003041218N1
- Lead Sponsor
- Tehran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 322
Inclusion Criteria
men and women aged over 20 years
without previously diagnosed CAD
Exclusion Criteria
non compliance
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Mean of systolic blood pressure in mm Hg from baseline. Timepoint: 10 months from baseline. Method of measurement: In clinic with standardized sphygmomanometer.;Mean change in diastolic blood pressure in mm Hg from baseline. Timepoint: 10 months from baseline. Method of measurement: In clinic with standardized sphygmomanometer.;Mean change in total cholesterol in milligram / deciliter from baseline. Timepoint: 10 months from baseline. Method of measurement: Laboratory enzymatic method.;Mean change in fasting blood sugar in milligram / deciliter from baseline. Timepoint: 10 months from baseline. Method of measurement: Laboratory enzymatic method.;Mean change in Reynolds risk score from baseline. Timepoint: 10 months from baseline. Method of measurement: statistical calculation method.
- Secondary Outcome Measures
Name Time Method